
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics Inc. is strategically positioned to enhance its clinical updates and strategic options, which could positively influence sentiment leading up to significant clinical readouts. The company stands out among independent late-stage metabolic developers, benefiting from a scarcity premium as the competitive landscape becomes more concentrated, further highlighting its maturity and strong data capabilities. With promising clinical candidates like VK2735 and an upcoming amylin agonist IND, Viking is well-equipped to attract favorable partnerships and financing, potentially improving its market presence in the expanding metabolic disorders sector.
Bears say
Viking Therapeutics Inc. operates within a highly competitive and unpredictable biotechnology sector, which presents numerous risks such as unexpected clinical outcomes and regulatory hurdles that can significantly impact its financial prospects. Additionally, the company faces challenges related to the complex and price-sensitive nature of commercial markets for its product candidates, potentially limiting revenue generation and profitability. The increased scrutiny over licensing deals, particularly in the context of US-China relations, further compounds the uncertainties surrounding Viking's strategic partnerships and market opportunities.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares